Inactive Instrument

Other languages CytRx Corporation Other OTC

Equities

LadRx: Q1 Earnings Snapshot	05-15
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	01-12
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	01-11
LadRx Issues 2024 Update to Shareholders	01-09
LadRx: Q3 Earnings Snapshot	11-14
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
LadRx : Modification to Rights of Security Holders - Form 8-K	23-09-11
LadRx: Q2 Earnings Snapshot	23-08-14
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Investor Presentation: July 2023	23-07-14
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	23-06-22
LadRx Announces Reverse Stock Split Effective as of May 17, 2023	23-05-18
Reverse Split: 1 of 100	23-05-16	FA
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
LadRx Announces Reverse Stock Split	23-05-10
LadRx Corporation has filed an IPO in the amount of $24 million.	23-04-14
LadRx Highlights Patent Issued for Its LADR Technology	23-03-27
LadRx Highlights Patent Issued for Its LADR Technology	23-03-27

No results for this search